摘要
目的探讨血清TNF-α、IL-6、IL-8检测在重症支原体肺炎患儿中的应用价值。方法选取我院于2012年4月至2015年2月入院治疗的支原体肺炎儿童患者90例,观察组45例为重症支原体肺炎,对照组45例为一般支原体肺炎,采用流式荧光法,测定患儿发病极期、恢复期血清TNF-α、IL-6及IL-8的水平。结果观察组与治疗组TNF-α、IL-6及IL-8在极期时的值分别为1.13±0.21、230.5±36.4、0.26±0.08 pg/m L和0.82±0.17、185±31.1、0.18±0.04 pg/m L,差异具有统计学意义(P<0.05);在恢复期,观察组与治疗组TNF-α、IL-6及IL-8的值分别为0.81±0.34、135.32±30.8、0.162±0.07 pg/m L和0.62±0.12、109.24±25.5、0.140±0.02 pg/m L,差异具有统计学意义(P<0.05);两组患者,血清中TNF-α、IL-6及IL-8水平治疗后均显著降低,前后差异具有统计学意义(P<0.05)。结论 TNF-α、IL-6及IL-8等炎性细胞因子在重症支原体肺炎的发生发展和疾病转归中起重要作用,可作为监测支原体肺炎严重程度的指标。
Objective To investigate serum TNF-α （tumor necrosis factor -α, IL-6 （interleukin-6）, IL-8 （ interleukin- 8 ） detection in children with severe mycoplasma pneumoniae pneumonia. Methods We collected 90 pediatric patients with refractory mycoplasma pneumoniae pneumonia who were admitted in our hospital were selected from April 2012 to February 2015. In the observation group, there were 45 patients with severe mycoplasma pneumoniae pneumonia, in the control group, there were 45 patients with mycoplasma pneumoniae pneumonia. TNF-α, IL-6 and IL-8 levels were detected at different clinical stages. Results The levels of TNF-α, IL-6 and IL-8 of observation group in the acute phase were 1.13±0.21, 230.5±36.4 and 0.26 ± 0.08, and treatment group were 0.82± 0.17, 185 ± 31.1,0.18 ± 0.04. The difference between two groups were statistically significant （P 〈 0.05 ） ; In the recovery phase, the levels of TNF-α, IL-6 and IL-8 of observation group were 0.81 ± 0.34, 135.32 ± 30.8 and 0. 162 ± 0.07 and treatment group were 0.62 ±0. 12, 109. 24 ± 25. 5 and 0. 140 ± 0. 02 The difference between two groups were statistically significant （P 〈 0.05 ）. TNF-α, IL-6 and IL-8 levels significantly reduced after treatment in both groups The differences between before and after treatment were statistically significant （P 〈 0. 05 ）. Conclusion TNF-α, IL-6 and IL-8 like other inflammatory cytokines play important roles in the development and prognosis of severe Mycoplasma pneumoniae pneumonia. They can be used as indicators to monitor the severity of the disease.
出处
《标记免疫分析与临床》
CAS
2016年第9期986-988,1015,共4页
Labeled Immunoassays and Clinical Medicine
